Target Expression, Generation, Mechanism of Action, Preclinical Activity and Pharmacokinetics of EM801, an IgG-based BCMA T-cell Bispecific Antibody for the Treatment of Multiple Myeloma
We assessed BCMA as target for T-cell immunotherapy and generated/evaluated the BCMA-TCB EM801 for treatment of multiple myeloma, a malignant plasma cell disease. We identified BCMA as excellent target, including high-risk/refractory patients. EM801 shows high single agent activity, even in heavily-pretreated patients, without significant toxicity. Together with a weekly administration schedule, EM801 appears as attractive non-cross-resistant compound with high potential for single agent, combination, or long-term maintenance treatment in myeloma.
Dirk Hose, M.D. -
Head, Multiple Myeloma Research Laboratory, Department of Internal Medicine,